AML study correlates gene mutations with 34 disease subgroups
Columbus, Ohio – A large, new study of adults with acute myeloid leukemia (AML) correlates 80 cancer-related gene mutations with five subtypes of AML, which are defined by the presence of specific chromosomal abnormalities. The findings might help guide mutation testing and treatment decisions in the future.
Led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), the study involved 1,603 newly diagnosed adult AML patients, who were treated on Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology trials in multiple centers across the United States .
The researchers combined the cytogenetic abnormalities that define each of 34 AML subgroups with the mutation status of the 80 cancer-related genes to produce an "oncoprint," a compact tabular summary of the gene mutations associated with each cytogenetic group.
Reported in the journal Leukemia, the findings identify:
- Potentially important genetic differences among the 34 subgroups;
- Unexpected associations between the AML subsets and both specific gene mutations and gene functional groups;
- Significant differences in cytogenetic and mutational features between patients younger than 60 years of age and those 60 years and older;
"Our study summarizes cytogenetic and mutational information of 1,603 AML patients in a single image," says first author and OSUCCC – James researcher Ann-Kathrin Eisfeld, MD, a member of Ohio State's Internal Medicine/Physician-Scientist Training Program. "The identification of key mutational features of each subgroup may help us to better understand the pathogenesis of the different AML types and provides a wealth of information for ongoing and future research."
Senior investigator Clara D. Bloomfield, MD, Distinguished University Professor, Ohio State University Cancer Scholar and Senior Adviser to the OSUCCC – James, adds: "If our findings are confirmed, it may mean that our mutational oncoprint may help to guide mutation testing and potentially even future treatment decisions for patients."
For this study, Eisfeld, Bloomfield and their colleagues obtained pretreatment bone marrow or peripheral blood samples from each patient. Of the patients, 1,080 were under age 60, and 523 were 60 years or older. All received similar treatment through Cancer and Leukemia Group B clinical trials.
Each patient's diagnosis placed him or her into one of five AML types and one of 34 subgroups, according to the presence or absence of specific chromosomal abnormalities in the person's leukemic cells. (AML patients with no chromosomal abnormalities are classified as having cytogenetically normal AML [CN-AML].)
The patients' leukemic cells were sequenced to learn the mutational status of 80 cancer- and leukemia-related genes. The mutations were assigned to one of nine categories based on the gene's biological function (e.g., methylation-related, cohesin complex, chromatin remodeling, tumor-suppressor genes).
The researchers identified 4,390 gene mutations in the patient cohort, with a median three mutations per patient. Overall, the most frequently mutated genes that contributed to AML in this cohort belonged to the methylation group.
Key genetic differences revealed by the mutational oncoprint include:
- A high incidence of mutations in methylation-related genes in patients with CN-AML, complex karyotype AML or unbalanced abnormalities;
- In contrast, mutations in methylation-related genes were almost absent in core-binding factor AML (CBF-AML) patients or were rather rare in patients with non-CBF-AML-related balanced translocations or inversions.
- Mutations in spliceosome genes were frequent in patients with unbalanced chromosomal abnormalities, especially those with sole trisomy of chromosomes 4, 8, 11, 13 or 21.
Funding from the National Cancer Institute of the National Institutes of Health (CA031946, CA033601, CA180821 and CA180882, CA101140, CA180850, CA180866, CA18086, CA032291, CA035279, CA047545, CA059518, CA077658, CA016058, CA140158, CA180821, CA180882, CA196171, CA197734, CA016058), the Coleman Leukemia Research Foundation, The D. Warren Brown Foundation and the Pelotonia Fellowship Program supports this research.
Other researchers involved in this study were Krzysztof Mrózek, Christopher J. Walker, Shelley Orwick, Karl W. Kroll, James S. Blachly, Albert de la Chapelle, and John C. Byrd, The Ohio State University; Deedra Nicolet and Jessica Kohlschmidt,, The Ohio State University and Alliance Statistics and Data Center; Andrew J. Carroll, University of Alabama at Birmingham; Jonathan E. Kolitz, Hofstra North Shore-Long Island Jewish School of Medicine; Bayard L. Powell, Wake Forest University; Eunice S. Wang, Roswell Park Cancer Institute; and Richard M. Stone, Dana-Farber/Partners CancerCare.
About the OSUCCC – James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program's 308-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors and with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. For more information, please visit cancer.osu.edu.